海南天羽飞行训练有限公司 审计报告 众环审字[2025]1700093 号 海南天羽飞行训练有限公司 财务报表附注 海南天羽飞行训练有限公司 财务报表附注 （除特别说明外，金额单位为人民币元） 一、公司基本情况 （一）基本情况 海南天羽飞行训练有限公司（以下简称"本公司"或"公司"）于2015年11月经 海南省市场监督管理局注册成立，取得了统一社会信用代码为91460000MA5RC58008 的营业执照。本公司注册地址和办公地址均为海南省海口市琼山区龙塘镇潭口村。 本公司及子公司（统称"本集团"）主要从事飞行员、乘务员等与航空相关人 员的培训服务。 （二）重大资产重组情况概述 海南航空控股股份有限公司（以下简称"海航控股"）拟受让海南空港开发产 业集团有限公司（以下简称"海南空港"）持有的海南天羽飞行训练有限公司（以 下简称"天羽飞训"）100%股权。 二、财务报表的编制基础 本财务报表仅为上述"一、公司基本情况"中所述的拟实施的重大资产重组交 易之参考目的编制，仅供本公司向上海证券交易所等机构报送重大资产重组申报材 料之用，不做其他用途。 鉴于以上特殊编制目的，本财务报表2025年1-4月、2024年度和 ...

Core Viewpoint - The independent financial advisor, China Galaxy Securities, conducted a thorough review of the impact of Hainan Airlines' major asset acquisition on the company's immediate return per share, concluding that the transaction will not dilute the earnings per share (EPS) and may enhance profitability in the future [1][4]. Group 1: Impact on Earnings - The transaction is expected to improve the net profit attributable to shareholders, with the projected basic EPS increasing from -0.0213 yuan/share to -0.0195 yuan/share post-transaction [1]. - The net profit before the transaction was -126,357.1 million yuan, which is expected to improve to -120,069.2 million yuan after the transaction [1]. Group 2: Measures to Enhance Returns - The company plans to integrate flight training operations into its business, enhancing the overall strategic development and operational efficiency [2]. - Measures include improving management efficiency, optimizing resource allocation, and exploring new growth opportunities to enhance profitability [2]. Group 3: Commitments from Management - The controlling shareholder and management have made commitments to ensure that measures to mitigate any potential dilution of immediate returns are effectively implemented [3][4]. - These commitments align with regulatory requirements aimed at protecting the rights of minority investors [4].

Group 1 - Hainan Airlines Holdings Co., Ltd. is planning a significant asset restructuring and has disclosed the draft asset purchase report on June 7, 2025 [1] - The independent financial advisor for the restructuring project is China Galaxy Securities Co., Ltd. [1] - The signing accountants for the project have changed from Li Hui and Cui Xiurong to Cui Xiurong and Su Wenjuan due to Li Hui's signing period expiring after five years [1] Group 2 - Su Wenjuan has been engaged in listed audit services since 2014 and became a Chinese certified public accountant in 2017, possessing extensive experience in the field [1] - Both Cui Xiurong and Su Wenjuan have agreed to assume their respective responsibilities and have committed to the authenticity, accuracy, and completeness of the documents they sign [2] - The independent financial advisor has reviewed the special report issued by Cui Xiurong and Su Wenjuan, confirming that they have fulfilled their due diligence obligations and that the changes will not adversely affect the transaction [2]

Core Viewpoint - The company, Debang Lighting, plans to initiate a significant asset restructuring to optimize its industrial structure and enhance profitability and asset quality [2][6]. Group 1: Transaction Details - On August 27, Debang Lighting announced its intention to acquire at least 51% of Zhejiang Jiali (Lishui) Industrial Co., Ltd. (referred to as "Jiali Co.") through cash payments for share acquisition and capital increase [5][6]. - Jiali Co. is a New Third Board listed company specializing in the research, design, manufacturing, and sales of automotive lighting products, with projected revenues of 2.68 billion yuan and 1.32 billion yuan for 2024 and the first half of 2025, respectively [5][6]. - The transaction is still in the planning stage, with specific transaction methods, counterparties, and acquisition ratios yet to be determined [6][7]. Group 2: Strategic Implications - If the transaction is successfully completed, Debang Lighting will gain control over Jiali Co., which is expected to enhance the company's operational scale and performance, thereby strengthening its second growth curve and core competitiveness [7]. - The transaction will require higher standards in operational management, financial management, and strategic planning, prompting the company to improve human resource allocation and overall operational capabilities [7].

Group 1 - The company, Debang Lighting, plans to initiate a significant asset restructuring to optimize its industrial structure and enhance profitability and asset quality [1][2] - The company intends to acquire at least 51% of Zhejiang Jiali Industrial Co., Ltd. (Jiali Shares) through cash transactions, which will grant it control over Jiali Shares [1][2] - Jiali Shares is a well-known domestic automotive lighting manufacturer, specializing in the research, design, manufacturing, and sales of automotive lamps [1][2] Group 2 - The projected revenues for Jiali Shares are 2.68 billion yuan and 1.32 billion yuan for 2024 and the first half of 2025, respectively, with net profits of 87.96 million yuan and 30.25 million yuan [1] - The transaction is currently in the planning stage, with a signed letter of intent, but specific transaction methods and acquisition ratios still require further discussion and negotiation [2] - If the transaction is successfully completed, it will enhance the company's operational scale and performance, strengthening its core competitiveness and sustainable development capabilities [3]

Group 1 - The company, Debang Lighting (603303), plans to initiate a major asset restructuring to optimize its industrial structure and enhance profitability and asset quality [1][2] - The company intends to acquire at least 51% of Zhejiang Jiali (Lishui) Industrial Co., Ltd. (referred to as "Jiali Co.") through cash transactions, which will grant control over Jiali Co. [1][2] - Jiali Co. is a well-known domestic automotive lighting manufacturer in China, specializing in the research, design, manufacturing, and sales of automotive lamps [1][2] Group 2 - The transaction is currently in the planning stage, with a signed letter of intent, but specific transaction methods, counterparties, and acquisition ratios still require further verification and negotiation [2][3] - Upon completion of the transaction, Jiali Co. will become a subsidiary of the listed company and will be included in the consolidated financial statements [2] - The latest semi-annual report indicates that Debang Lighting's revenue for the first half of 2025 was 2.152 billion yuan, a year-on-year increase of 0.4%, while net profit decreased by 19.66% to 143 million yuan [2]

Core Viewpoint - The company, DEBANG Lighting, plans to acquire at least 51% of Zhejiang Jiali (Lishui) Industrial Co., Ltd. to gain control through cash payment via share transfer and capital increase, which is expected to constitute a major asset restructuring [1] Group 1: Company Overview - Zhejiang Jiali specializes in the research, design, manufacturing, and sales of automotive lighting for both passenger and commercial vehicles, as well as a small amount of motorcycle lighting and mold supporting business [1] - Jiali is recognized as a well-known domestic automotive lighting manufacturer in China [1] Group 2: Transaction Details - The specific transaction method, counterparties, and acquisition ratio are still under further verification and negotiation [1] - The preliminary assessment indicates that this transaction will be significant in nature, likely impacting the company's financial structure and market position [1]

Core Viewpoint - The significant increase in the stock price of Nanjing New Pharmaceutical Co., Ltd. is attributed to the announcement of a major asset restructuring involving the acquisition of specific assets from Future Pharmaceutical, which is expected to enhance the company's product offerings and financial performance [1][3]. Group 1: Asset Acquisition Details - Nanjing New Pharmaceutical signed an acquisition agreement to purchase specific assets from Future Pharmaceutical for no more than 480 million yuan [3]. - The asset group includes already marketed products "Multiple Trace Element Injection (I)" and "Multiple Trace Element Injection (II)", as well as the in-development "Multiple Trace Element Injection (III)" [3]. - The acquisition will not involve share issuance or constitute a related party transaction, and it will not change the company's control [3]. Group 2: Financial Performance Context - In 2021, the company reported a revenue of 685 million yuan, a decrease of 37.08% year-on-year, and a net loss of 167 million yuan, a decline of 225.50% compared to the previous year [4]. - The company has faced continuous losses since 2021, with a projected loss of 397 million yuan in 2024, attributed to industry policy changes and increased market competition [4]. - The company aims to improve its performance through this asset restructuring, which is seen as a strategic move to enhance revenue and profitability [4]. Group 3: Strategic Implications - The acquisition is expected to enrich the company's product pipeline and enhance its "whole-age health management" product matrix [5]. - The existing sales channels and academic promotion systems of Future Pharmaceutical will provide new sales opportunities for the company's products, particularly in expanding the market for pediatric anti-influenza medications [6].

Core Viewpoint - The article discusses the significant asset restructuring of Hunan Nanxin Pharmaceutical Co., Ltd., which aims to enhance its product pipeline and improve financial performance following a period of continuous losses [2][5][7]. Group 1: Company Overview - Hunan Nanxin Pharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of antiviral and infectious disease treatment drugs, as well as medications for major diseases like cancer and diabetes [5]. - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020 [5]. Group 2: Financial Performance - In 2021, the company reported a revenue of 685 million yuan, a decrease of 37.08% year-on-year, and a net loss of 167 million yuan, a decline of 225.50% compared to the previous year [5]. - The company has faced continuous losses since 2021, with a projected loss of 397 million yuan in 2024, attributed to industry policy changes and intensified market competition [6]. Group 3: Asset Restructuring - On August 26, 2023, the company announced a cash acquisition of specific assets from Future Pharmaceutical for no more than 480 million yuan, which includes already marketed and in-development products [4][5]. - This acquisition is expected to enhance the company's product offerings and improve its revenue and profit potential, particularly through established sales channels and academic promotion systems [7].

Group 1 - The company announced a cash acquisition of assets from Future Pharmaceuticals for no more than 480 million yuan, including three types of microelement injection solutions and related intellectual property [1] - This acquisition is expected to constitute a significant asset restructuring and will not involve share issuance or change in control [1] - The company plans to disclose a formal proposal related to the transaction within six months and will continue to fulfill information disclosure obligations as necessary [1] Group 2 - The acquisition will enrich the company's product pipeline and align with its "health management for all ages" strategy, optimizing its product layout in the "anti-infection - chronic disease - nutritional support" sectors [2] - The microelement injection solutions have already established market sales, which could provide immediate revenue and profit growth for the company, enhancing its operational sustainability and profitability [2] - The acquired assets include a mature national sales channel and academic promotion system, which will help the company expand sales channels for its products, particularly in the pediatric flu medication market [2] Group 3 - The company specializes in antiviral and infectious disease prevention drugs, as well as treatments for major diseases like cancer and cardiovascular diseases [3] - It has developed a combined R&D system for innovative and generic drugs, with a production chain covering over 30 provinces in China [3] - The company reported a revenue of 40.62 million yuan in Q1 2025, a year-on-year decline of 70.21%, with a net loss of 8.03 million yuan [3]